ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Head and neck surgery recommendations during the COVID-19 pandemic [Carta] (2020)
Galloway, Thomas J; Kowalski, Luiz Paulo ; Matos, Leandro L; Castro Junior, Gilberto de Castro ; Ridge, John A
Fonte: Lancet oncology. Unidade: FM
Assuntos: COVID-19, INFECÇÕES POR CORONAVIRUS, PANDEMIAS, ONCOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GALLOWAY, Thomas J et al. Head and neck surgery recommendations during the COVID-19 pandemic [Carta]. Lancet oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://observatorio.fm.usp.br/handle/OPI/37600. Acesso em: 31 out. 2024. , 2020
APA
Galloway, T. J., Kowalski, L. P., Matos, L. L., Castro Junior, G. de C., & Ridge, J. A. (2020). Head and neck surgery recommendations during the COVID-19 pandemic [Carta]. Lancet oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://observatorio.fm.usp.br/handle/OPI/37600
NLM
Galloway TJ, Kowalski LP, Matos LL, Castro Junior G de C, Ridge JA. Head and neck surgery recommendations during the COVID-19 pandemic [Carta] [Internet]. Lancet oncology. 2020 ; 21( 9): E416-E416.[citado 2024 out. 31 ] Available from: https://observatorio.fm.usp.br/handle/OPI/37600
Vancouver
Galloway TJ, Kowalski LP, Matos LL, Castro Junior G de C, Ridge JA. Head and neck surgery recommendations during the COVID-19 pandemic [Carta] [Internet]. Lancet oncology. 2020 ; 21( 9): E416-E416.[citado 2024 out. 31 ] Available from: https://observatorio.fm.usp.br/handle/OPI/37600
Artigo de periodico
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study (2020)
Strom, Peter; Kartasalo, Kimmo; Olsson, Henrik; Solorzano, Leslie; Delahunt, Brett; Berney, Daniel M.; Bostwick, David G; Evans, Andrew J; Grignon, David J; Leite, Katia Ramos Moreira
Fonte: Lancet oncology. Unidade: FM
Assuntos: INTELIGÊNCIA ARTIFICIAL, NEOPLASIAS PROSTÁTICAS, BIÓPSIA POR AGULHA, DESENVOLVIMENTO DE TECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STROM, Peter et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet oncology, v. 21, n. 2, p. 222-232, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30738-7. Acesso em: 31 out. 2024.
APA
Strom, P., Kartasalo, K., Olsson, H., Solorzano, L., Delahunt, B., Berney, D. M., et al. (2020). Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet oncology, 21( 2), 222-232. doi:10.1016/S1470-2045(19)30738-7
NLM
Strom P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Leite KRM. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study [Internet]. Lancet oncology. 2020 ; 21( 2): 222-232.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30738-7
Vancouver
Strom P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Leite KRM. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study [Internet]. Lancet oncology. 2020 ; 21( 2): 222-232.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30738-7
Artigo de periodico
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial (2020)
Coleman, Robert; Finkelstein, Dianne M; Barrios, Carlos; Martin, Miguel; Iwata, Hiroji; Hegg, Roberto; Glaspy, John; Perianez, Alvaro Montano; Tonkin, Katia; Deleu, Ines
Fonte: Lancet oncology. Unidade: FM
Assuntos: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA ADJUVANTE, ANTICORPOS MONOCLONAIS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, NEOPLASIAS ÓSSEAS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COLEMAN, Robert et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, v. 21, n. 1, p. 60-72, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(19)30687-4. Acesso em: 31 out. 2024.
APA
Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., et al. (2020). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet oncology, 21( 1), 60-72. doi:10.1016/S1470-2045(19)30687-4
NLM
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Vancouver
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Perianez AM, Tonkin K, Deleu I. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [Internet]. Lancet oncology. 2020 ; 21( 1): 60-72.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(19)30687-4
Artigo de periodico
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
Smith, Matthew; Parker, Chris; Saad, Fred; Miller, Kurt; Tombal, Bertrand; Ng, Quan Sing; Boegemann, Martin; Matveev, Vsevolod; Piulats, Josep Maria; Zucca, Luis Eduardo; Nahas, William Carlos
Fonte: Lancet oncology. Unidade: FM
Assuntos: NEOPLASIAS PROSTÁTICAS, METÁSTASE NEOPLÁSICA, NEOPLASIAS ÓSSEAS, ESTEROIDES, ANDRÓGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SMITH, Matthew et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, v. 20, n. 3, p. 408-419, 2019Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30860-X. Acesso em: 31 out. 2024.
APA
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., et al. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20( 3), 408-419. doi:10.1016/S1470-2045(18)30860-X
NLM
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X
Vancouver
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X
Artigo de periodico
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study (2018)
Robak, Tadeusz; Jin, Jie; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Drach, Johannes; Raderer, Markus; Mayer, Jiri; Pereira, Juliana; Tumyan, Gayane
Fonte: Lancet oncology. Unidade: FM
Assuntos: LINFOMA, IMUNOTERAPIA, ESTUDOS RANDOMIZADOS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, v. 19, n. 11, p. 1449-1458, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30685-5. Acesso em: 31 out. 2024.
APA
Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, 19( 11), 1449-1458. doi:10.1016/S1470-2045(18)30685-5
NLM
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5
Vancouver
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Agência de fomento